Telix Pharmaceuticals LimitedASX: TLX

Grant of waivers of Listing Rule 7.3.4

· Issued by Telix Pharmaceuticals Limited via ASX

Filed with ASX · · 4 pages · English

Summary by 6ix AI

The waivers allow Telix to seek shareholder approval for issuing shares as part of the acquisition consideration beyond the usual three-month period after the extraordinary general meeting. The filing outlines the nature and effect of the waivers, as well as the reasons for seeking them, emphasizing the need for flexibility in the timing of share issuance.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Page 1 ASX Listing Rule 7.3.4 Waivers Granted in Connection with Telix’s Proposed Acquisition of ITM Melbourne (Australia) and Indianapolis, IN (U.S.) – September 22,...

Telix Pharmaceuticals Limited on 6ix

In the deck

Earlier from Telix Pharmaceuticals

Later from Telix Pharmaceuticals

All Telix Pharmaceuticals news releases